Grant Number:	5R01CA231141-05 Interpret this number
Primary Investigator:	Afshar-Kharghan, Vahid
Organization:	University Of Tx Md Anderson Can Ctr
Project Title:	Genetics of Graft-Versus-Host Disease
Fiscal Year:	2022

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for many advanced hematologic malignancies. Allo-HSCT is associated with significant morbidities and mortality, mainly because of the graft-versus-host disease (GVHD) caused by donor T cells recognizing antigens present in recipient tissues, and initiating an alloimmune response resulting in damage to many organs including the skin, GI tract, and liver in recipient. More than half of all allo-HSCT recipients develop different degrees of GVHD (grade I-IV). About 20% of recipients develop severe GVHD (grade III-IV) that is associated with a very high morbidity and mortality. The most important factor determining the severity of GVHD is the genetic disparities between donors and recipients, as is reflected in HLA haplotypes that are routinely checked for donor selection. But even when donors and recipients are HLA-identical many recipients develop severe GVHD. As a result, non-HLA antigens are important determinants of acute GVHD. An interesting and unique aspect of GVHD is that it is the consequence of an interaction between antigens present in one individual with the immune system of another individual. As a result, genotypes of both donor and recipient, and their interactions affect the pathogenesis of GVHD. To determine the genetic risk factors for GVHD, in the first aim (discovery phase), we will conduct Genome-Wide Association Studies (GWAS) in 3,000 patients who underwent allo-HSCT and in their respective donors (6000 DNA samples) that are provided to us by the National Marrow Donor Program (NMDP) and the Center for International Blood and Marrow Transplant Research (CIBMTR). This part of our grant is approved by the Center for Inherited Disease Research (CIDR) and will be conducted in their sequencing facility. We expect that 3000 recipients will be stratified into 1200 subjects with moderate to severe acute GVHD (grades II-IV) versus 1800 individuals with none to mild GVHD (grade 0-I). We will also include the existing GWAS and clinical outcome data on 7047 donor/recipient pairs available from two previous studies to augment our cohort with an estimated 2830 pairs with grade II-IV and 4244 pairs with grade 0-I GVHD, and investigate an association between the severity of acute GVHD and genotypes in donors or recipients, or mismatch of certain genotypes (other than HLA). In the second aim, we will validate the association between high risk genotypes detected in the aim 1 and severe GVHD in 1,750 donors and 1,750 recipients of allo-HSCT, and perform the joint analysis with the discovery samples (an estimated 4730 pairs with grade II-IV vs 7094 pairs with Grade 0-I GVHD). We will determine the frequency of 5000 single nucleotide polymorphisms (SNP), that GWAS in the aim 1 showed to be associated with severe GVHD and correlate it to the severity of GVHD. In the third aim, we will investigate the functional effect of SNPs detected and validated to be significantly correlated with the severity of acute GVHD in mixed lymphocyte reaction (MLR), as an Ex vivo surrogate for an alloimmune response.




Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.
Authors: Landsburg D.J. , Frigault M.J. , Heim M. , Foley S.R. , Hill B. , Schofield G. , Jacobson C.A. , Jaglowski S. , Locke F.L. , Ram R. , et al. .
Source: Journal For Immunotherapy Of Cancer, 2025-02-09 00:00:00.0; 13(2), .
EPub date: 2025-02-09 00:00:00.0.
PMID: 39924174
Related Citations

Multiscale 3D spatial analysis of the tumor microenvironment using whole-tissue digital histopathology.
Authors: Kermany D.S. , Ahn J.Y. , Vasquez M. , Zhang W. , Wang L. , Liu K. , Xu Z. , Cho M.S. , Carlos-Alcalde W. , Lee H. , et al. .
Source: Cancer Communications (london, England), 2025-01-03 00:00:00.0; , .
EPub date: 2025-01-03 00:00:00.0.
PMID: 39749685
Related Citations

CAST Regimen for GvHD Prophylaxis: A CIBMTR Propensity Score-Matched Analysis.
Authors: Al-Homsi A.S. , DeFor T.E. , Cole K. , Cirrone F. , King S. , Suarez-Londono A. , Yaghmour G. , Boisclair S. , Bupp C. , Spellman S.R. .
Source: Transplantation And Cellular Therapy, 2024 Nov; 30(11), p. 1092-1098.
EPub date: 2024-08-30 00:00:00.0.
PMID: 39209024
Related Citations

Applying Implementation Science in the Field of Transplant and Cellular Therapy.
Authors: DeSalvo A.M. , Spellman S.R. , Coles J.A.S. , Robb D. , McCann M. , Yusuf R.A. , Hengen M. , Auletta J.J. .
Source: Transplantation And Cellular Therapy, 2024 Sep; 30(9), p. 864-875.
EPub date: 2024-06-21 00:00:00.0.
PMID: 38909780
Related Citations

The effect of ADAMTS13 on graft-versus-host disease.
Authors: Li D. , Cho M.S. , Gonzalez-Delgado R. , Liang X. , Dong J.F. , Cruz M.A. , Ma Q. , Afshar-Kharghan V. .
Source: Journal Of Cellular And Molecular Medicine, 2024 Jul; 28(13), p. e18457.
PMID: 38963011
Related Citations

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
Authors: Locke F.L. , Siddiqi T. , Jacobson C.A. , Ghobadi A. , Ahmed S. , Miklos D.B. , Perales M.A. , Munoz J. , Fingrut W.B. , Pennisi M. , et al. .
Source: Blood, 2024-06-27 00:00:00.0; 143(26), p. 2722-2734.
PMID: 38635762
Related Citations

Prediction of KIR3DL1/Human Leukocyte Antigen binding.
Authors: Maiers M. , Louzoun Y. , Pymm P. , Vivian J.P. , Rossjohn J. , Brooks A.G. , Saunders P.M. .
Source: Biorxiv : The Preprint Server For Biology, 2024-05-05 00:00:00.0; , .
EPub date: 2024-05-05 00:00:00.0.
PMID: 38746109
Related Citations

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Authors: Lunning M.A. , Wang H.L. , Hu Z.H. , Locke F.L. , Siddiqi T. , Jacobson C.A. , Ahmed S. , Miklos D.B. , Lin Y. , Hill B.T. , et al. .
Source: American Journal Of Hematology, 2024 May; 99(5), p. 880-889.
EPub date: 2024-03-19 00:00:00.0.
PMID: 38504387
Related Citations

Mechanical Venous Thrombectomy for Deep Venous Thrombosis in Cancer Patients: A Single-Center Retrospective Study.
Authors: Patel R.M. , Pal K. , Ahmed S.H. , Kuban J.D. , Patel M. , Shah K. , Habibollahi P. , Metwalli Z. , Gurusamy V. , Gupta S. , et al. .
Source: Cardiovascular And Interventional Radiology, 2024 May; 47(5), p. 556-566.
EPub date: 2024-03-28 00:00:00.0.
PMID: 38548981
Related Citations

Role of circulating mitochondria in venous thrombosis in glioblastoma.
Authors: Gonzalez-Delgado R. , Muñoz N.M. , Carlos-Alcalde W. , Cho M.S. , Lee H. , Jin J. , Serpas V. , Gorlova O. , Sheth R.A. , Afshar-Kharghan V. .
Source: Journal Of Thrombosis And Haemostasis : Jth, 2023 Aug; 21(8), p. 2202-2212.
EPub date: 2023-05-11 00:00:00.0.
PMID: 37178770
Related Citations

Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population.
Authors: Shi J. , Shiraishi K. , Choi J. , Matsuo K. , Chen T.Y. , Dai J. , Hung R.J. , Chen K. , Shu X.O. , Kim Y.T. , et al. .
Source: Nature Communications, 2023-05-26 00:00:00.0; 14(1), p. 3043.
EPub date: 2023-05-26 00:00:00.0.
PMID: 37236969
Related Citations

Methylation of nonessential genes in cutaneous melanoma - Rule Out hypothesis.
Authors: Gorlov I.P. , Conway K. , Edmiston S.N. , Parrish E.A. , Hao H. , Amos C.I. , Tsavachidis S. , Gorlova O.Y. , Begg C. , Hernando E. , et al. .
Source: Melanoma Research, 2023-02-20 00:00:00.0; , .
EPub date: 2023-02-20 00:00:00.0.
PMID: 36805567
Related Citations

Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia.
Authors: Qiao W. , Young E. , Feng C. , Liu S. , Jin J. , Noor L. , Rojas Hernandez C.M. , Borthakur G. , Gorlova O. , Afshar-Kharghan V. .
Source: Experimental Hematology & Oncology, 2022-09-16 00:00:00.0; 11(1), p. 58.
EPub date: 2022-09-16 00:00:00.0.
PMID: 36114519
Related Citations

Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles.
Authors: Corvigno S. , Johnson A.M. , Wong K.K. , Cho M.S. , Afshar-Kharghan V. , Menter D.G. , Sood A.K. .
Source: Molecular Cancer Therapeutics, 2022-07-05 00:00:00.0; 21(7), p. 1067-1075.
PMID: 35545008
Related Citations

Platelets Increase the Expression of PD-L1 in Ovarian Cancer.
Authors: Cho M.S. , Lee H. , Gonzalez-Delgado R. , Li D. , Sasano T. , Carlos-Alcalde W. , Ma Q. , Liu J. , Sood A.K. , Afshar-Kharghan V. .
Source: Cancers, 2022-05-19 00:00:00.0; 14(10), .
EPub date: 2022-05-19 00:00:00.0.
PMID: 35626102
Related Citations

Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer.
Authors: Glassman D. , Bateman N.W. , Lee S. , Zhao L. , Yao J. , Tan Y. , Ivan C. , Rangel K.M. , Zhang J. , Conrads K.A. , et al. .
Source: Cancers, 2022-03-15 00:00:00.0; 14(6), .
EPub date: 2022-03-15 00:00:00.0.
PMID: 35326647
Related Citations

Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Authors: Sidana S. , Kumar S. , Fraser R. , Estrada-Merly N. , Giralt S. , Agrawal V. , Anderson L.D. , Aljurf M. , Banerjee R. , Bashey A. , et al. .
Source: Transplantation And Cellular Therapy, 2022 Feb; 28(2), p. 83.e1-83.e9.
EPub date: 2021-11-12 00:00:00.0.
PMID: 34781066
Related Citations

Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.
Authors: Menter D.G. , Afshar-Kharghan V. , Shen J.P. , Martch S.L. , Maitra A. , Kopetz S. , Honn K.V. , Sood A.K. .
Source: Cancer Metastasis Reviews, 2022-01-12 00:00:00.0; , .
EPub date: 2022-01-12 00:00:00.0.
PMID: 35022962
Related Citations

SNP characteristics and validation success in genome wide association studies.
Authors: Gorlova O.Y. , Xiao X. , Tsavachidis S. , Amos C.I. , Gorlov I.P. .
Source: Human Genetics, 2022-01-04 00:00:00.0; , .
EPub date: 2022-01-04 00:00:00.0.
PMID: 34981173
Related Citations

Identification of lung cancer drivers by comparison of the observed and the expected numbers of missense and nonsense mutations in individual human genes.
Authors: Gorlova O.Y. , Kimmel M. , Tsavachidis S. , Amos C.I. , Gorlov I.P. .
Source: Oncotarget, 2022; 13, p. 756-767.
EPub date: 2022-05-25 00:00:00.0.
PMID: 35634240
Related Citations

An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
Authors: Jimenez Jimenez A.M. , De Lima M. , Komanduri K.V. , Wang T.P. , Zhang M.J. , Chen K. , Abdel-Azim H. , Abid M.B. , Aljurf M. , Alkhateeb H. , et al. .
Source: Bone Marrow Transplantation, 2021 Dec; 56(12), p. 3068-3077.
EPub date: 2021-09-28 00:00:00.0.
PMID: 34584240
Related Citations

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older.
Authors: Munshi P.N. , Vesole D.H. , St Martin A. , Davila O. , Kumar S. , Qazilbash M. , Shah N. , Hari P.N. , D'Souza A. .
Source: Cancer, 2021-11-15 00:00:00.0; 127(22), p. 4233-4239.
EPub date: 2021-08-10 00:00:00.0.
PMID: 34374445
Related Citations

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.
Authors: Metheny L. , Callander N.S. , Hall A.C. , Zhang M.J. , Bo-Subait K. , Wang H.L. , Agrawal V. , Al-Homsi A.S. , Assal A. , Bacher U. , et al. .
Source: Transplantation And Cellular Therapy, 2021 11; 27(11), p. 923.e1-923.e12.
EPub date: 2021-08-21 00:00:00.0.
PMID: 34428556
Related Citations

Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer.
Authors: Sasano T. , Gonzalez-Delgado R. , Muñoz N.M. , Carlos-Alcade W. , Cho M.S. , Sheth R.A. , Sood A.K. , Afshar-Kharghan V. .
Source: Journal Of Thrombosis And Haemostasis : Jth, 2021-10-04 00:00:00.0; , .
EPub date: 2021-10-04 00:00:00.0.
PMID: 34608736
Related Citations

Barriers to Access to Hematopoietic Cell Transplantation among Patients with Acute Myeloid Leukemia in Virginia.
Authors: Mock J. , Meyer C. , Mau L.W. , Nguyen C. , Arora P. , Heron C. , Balkrishnan R. , Burns L. , Devine S. , Ballen K. .
Source: Transplantation And Cellular Therapy, 2021 10; 27(10), p. 869.e1-869.e9.
EPub date: 2021-07-02 00:00:00.0.
PMID: 34224915
Related Citations

Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation.
Authors: Hahn T. , Wang J. , Preus L.M. , Karaesmen E. , Rizvi A. , Clay-Gilmour A.I. , Zhu Q. , Wang Y. , Yan L. , Liu S. , et al. .
Source: Eclinicalmedicine, 2021 Oct; 40, p. 101093.
EPub date: 2021-08-25 00:00:00.0.
PMID: 34746714
Related Citations

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
Authors: Munshi P.N. , Hamadani M. , Kumar A. , Dreger P. , Friedberg J.W. , Dreyling M. , Kahl B. , Jerkeman M. , Kharfan-Dabaja M.A. , Locke F.L. , et al. .
Source: Transplantation And Cellular Therapy, 2021 Sep; 27(9), p. 720-728.
PMID: 34452722
Related Citations

Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease.
Authors: Mupfudze T.G. , Meyer C. , Preussler J.M. , Mau L.W. , Bolon Y.T. , Steinert P. , Arnold S.D. , Saber W. , Krishnamurti L. .
Source: Transplantation And Cellular Therapy, 2021 08; 27(8), p. 685.e1-685.e8.
EPub date: 2021-04-22 00:00:00.0.
PMID: 33895405
Related Citations

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation.
Authors: Mayor N.P. , Wang T. , Lee S.J. , Kuxhausen M. , Vierra-Green C. , Barker D.J. , Auletta J. , Bhatt V.R. , Gadalla S.M. , Gragert L. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2021-07-20 00:00:00.0; 39(21), p. 2397-2409.
EPub date: 2021-04-09 00:00:00.0.
PMID: 33835855
Related Citations

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
Authors: Wieduwilt M.J. , Stock W. , Advani A. , Luger S. , Larson R.A. , Tallman M. , Appelbaum F. , Zhang M.J. , Bo-Subait K. , Wang H.L. , et al. .
Source: Leukemia, 2021 Jul; 35(7), p. 2076-2085.
EPub date: 2021-03-30 00:00:00.0.
PMID: 33785862
Related Citations

Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.
Authors: Mishra A. , Preussler J.M. , Bhatt V.R. , Bredeson C. , Chhabra S. , D'Souza A. , Dahi P.B. , Hacker E.D. , Gowda L. , Hashmi S.K. , et al. .
Source: Transplantation And Cellular Therapy, 2021 Jul; 27(7), p. 617.e1-617.e7.
EPub date: 2021-04-06 00:00:00.0.
PMID: 33836312
Related Citations

Losing control to bad relatives.
Authors: Afshar-Kharghan V. .
Source: Blood, 2021-06-24 00:00:00.0; 137(25), p. 3462-3463.
PMID: 34165547
Related Citations

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.
Authors: Goldsmith S.R. , Abid M.B. , Auletta J.J. , Bashey A. , Beitinjaneh A. , Castillo P. , Chemaly R.F. , Chen M. , Ciurea S. , Dandoy C.E. , et al. .
Source: Blood, 2021-06-10 00:00:00.0; 137(23), p. 3291-3305.
PMID: 33657221
Related Citations

Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.
Authors: Panch S.R. , Logan B. , Sees J.A. , Bo-Subait S. , Savani B. , Shah N.N. , Hsu J.W. , Switzer G. , Lazarus H.M. , Anderlini P. , et al. .
Source: Transplantation And Cellular Therapy, 2021 Jun; 27(6), p. 503.e1-503.e8.
EPub date: 2021-03-09 00:00:00.0.
PMID: 33823169
Related Citations

Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning.
Authors: Logan B.R. , Maiers M.J. , Sparapani R.A. , Laud P.W. , Spellman S.R. , McCulloch R.E. , Shaw B.E. .
Source: Jco Clinical Cancer Informatics, 2021 05; 5, p. 494-507.
PMID: 33950708
Related Citations

Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee.
Authors: Sharma A. , Badawy S.M. , Suelzer E.M. , Murthy H.S. , Prasad P. , Eissa H. , Carpenter P.A. , Hamadani M. , Labopin M. , Schoemans H. , et al. .
Source: Transplantation And Cellular Therapy, 2021 05; 27(5), p. 380-388.
EPub date: 2021-01-28 00:00:00.0.
PMID: 33965174
Related Citations

COVID-19 and Hematopoietic Cell Transplant Center-specific survival analysis: Can we adjust for the impact of the pandemic? Recommendations of the COVID-19 Taskforce of the 2020 CIBMTR Center Outcomes Forum.
Authors: Wingard J.R. , Ahn K.W. , Dandoy C. , Perales M.A. , Wood W.A. , Logan B. , Riches M. , Rizzo J.D. .
Source: Transplantation And Cellular Therapy, 2021-04-22 00:00:00.0; , .
EPub date: 2021-04-22 00:00:00.0.
PMID: 33895401
Related Citations

The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer.
Authors: Cho M.S. , Li J. , Gonzalez-Delgado R. , Lee H. , Vasquez M. , He T. , He Y. , Liu K. , Sasano T. , Nürnberg B. , et al. .
Source: Blood Advances, 2021-04-13 00:00:00.0; 5(7), p. 1947-1951.
PMID: 33821990
Related Citations

Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee.
Authors: Sharma A. , Badawy S.M. , Suelzer E.M. , Murthy H.S. , Prasad P. , Eissa H. , Carpenter P.A. , Hamadani M. , Labopin M. , Schoemans H. , et al. .
Source: Bone Marrow Transplantation, 2021 Apr; 56(4), p. 786-797.
EPub date: 2021-01-29 00:00:00.0.
PMID: 33514917
Related Citations

Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study.
Authors: Seftel M.D. , Chitphakdithai P. , Miller J.P. , Kobusingye H. , Logan B.R. , Linenberger M. , Artz A.S. , Haight A.E. , Jacobsohn D.A. , Litzow M.R. , et al. .
Source: Transplantation And Cellular Therapy, 2021 Apr; 27(4), p. 352.e1-352.e5.
EPub date: 2021-01-15 00:00:00.0.
PMID: 33836890
Related Citations

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
Authors: Shah N.N. , Ahn K.W. , Litovich C. , He Y. , Sauter C. , Fenske T.S. , Hamadani M. .
Source: Blood, 2021-03-11 00:00:00.0; 137(10), p. 1416-1423.
PMID: 33120429
Related Citations

Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.
Authors: Cornell R.F. , Fraser R. , Costa L. , Goodman S. , Estrada-Merly N. , Lee C. , Hildebrandt G. , Gergis U. , Farhadfar N. , Freytes C.O. , et al. .
Source: Transplantation And Cellular Therapy, 2021 Mar; 27(3), p. 264.e1-264.e7.
EPub date: 2020-12-16 00:00:00.0.
PMID: 33781533
Related Citations

Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes.
Authors: Camacho-Bydume C. , Wang T. , Sees J.A. , Fernandez-Viña M. , Abid M.B. , Askar M. , Beitinjaneh A. , Brown V. , Castillo P. , Chhabra S. , et al. .
Source: Transplantation And Cellular Therapy, 2021 Feb; 27(2), p. 142.e1-142.e11.
EPub date: 2020-10-11 00:00:00.0.
PMID: 33053450
Related Citations

Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease
Authors: Elgarten C.W. , Li Y. , Getz K.D. , Hemmer M. , Huang Y.V. , Hall M. , Wang T. , Kitko C.L. , Jagasia M.H. , Nishihori T. , et al. .
Source: Transplantation And Cellular Therapy, 2021 02; 27(2), p. 177.e1-177.e8.
EPub date: 2020-12-21 00:00:00.0.
PMID: 33718896
Related Citations

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis.
Authors: Bona K. , Brazauskas R. , He N. , Lehmann L. , Abdel-Azim H. , Ahmed I.A. , Al-Homsi A.S. , Aljurf M. , Arnold S.D. , Badawy S.M. , et al. .
Source: Blood, 2021-01-28 00:00:00.0; 137(4), p. 556-568.
PMID: 33104215
Related Citations

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.
Authors: Sharma A. , Bhatt N.S. , St Martin A. , Abid M.B. , Bloomquist J. , Chemaly R.F. , Dandoy C. , Gauthier J. , Gowda L. , Perales M.A. , et al. .
Source: The Lancet. Haematology, 2021-01-19 00:00:00.0; , .
EPub date: 2021-01-19 00:00:00.0.
PMID: 33482113
Related Citations

Prognostic impact of serum CXC chemokine ligands 4 and 7 on myelodysplastic syndromes post allogeneic hematopoietic cell transplant.
Authors: Dhakal B. , Wang T. , Kuxhausen M. , Zhu F. , Taylor C. , Spellman S.R. , Verneris M.R. , Hsu K. , Fleischhauer K. , Lee S.J. , et al. .
Source: Leukemia & Lymphoma, 2021 01; 62(1), p. 229-233.
EPub date: 2020-09-13 00:00:00.0.
PMID: 32924688
Related Citations

The Provocative Roles of Platelets in Liver Disease and Cancer.
Authors: Kanikarla Marie P. , Fowlkes N.W. , Afshar-Kharghan V. , Martch S.L. , Sorokin A. , Shen J.P. , Morris V.K. , Dasari A. , You N. , Sood A.K. , et al. .
Source: Frontiers In Oncology, 2021; 11, p. 643815.
EPub date: 2021-07-21 00:00:00.0.
PMID: 34367949
Related Citations

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
Authors: Hagen P. , D'Souza A. , Hari P. , Davila O. , Zhang M.J. , Vesole D.H. , Smith S.E. , Rodriguez T.E. , Stiff P.J. .
Source: Leukemia & Lymphoma, 2020 12; 61(14), p. 3484-3492.
EPub date: 2020-08-31 00:00:00.0.
PMID: 32865474
Related Citations

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Authors: Munshi P.N. , Vesole D. , Jurczyszyn A. , Zaucha J.M. , St Martin A. , Davila O. , Agrawal V. , Badawy S.M. , Battiwalla M. , Chhabra S. , et al. .
Source: Cancer, 2020-12-01 00:00:00.0; 126(23), p. 5077-5087.
EPub date: 2020-09-23 00:00:00.0.
PMID: 32965680
Related Citations